Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Omeros Corporation has a consensus rating of "Moderate Buy" from six brokerages, with two hold recommendations, three buy recommendations, and one strong buy recommendation.
• The average 12-month price target for Omeros' stock among analysts is $18.00, despite recent downgrades from some research firms.
• Omeros' stock opened at $3.70, with a market capitalization of $228.51 million and a 1-year low of $2.95.

Omeros Corporation (NASDAQ:OMER - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six brokerages that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $18.00.

A number of research firms recently weighed in on OMER. Wall Street Zen downgraded Omeros from a "hold" rating to a "sell" rating in a research report on Friday, June 27th. Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a research report on Friday, May 16th. HC Wainwright reiterated a "buy" rating and issued a $9.00 price objective on shares of Omeros in a research report on Friday, June 27th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $36.00 price objective on shares of Omeros in a research report on Friday, July 25th.

Omeros Price Performance

NASDAQ:OMER opened at $3.70 on Tuesday. The business has a 50 day moving average of $3.44 and a 200 day moving average of $6.06. The company has a market capitalization of $228.51 million, a price-to-earnings ratio of -1.40 and a beta of 2.26. Omeros has a 1-year low of $2.95 and a 1-year high of $13.60.

Omeros (NASDAQ:OMER - Get Free Report) last released its earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.05). As a group, sell-side analysts anticipate that Omeros will post -3.09 EPS for the current year.

Hedge Funds Weigh In On Omeros

Several hedge funds have recently made changes to their positions in OMER. Nomura Holdings Inc. increased its stake in shares of Omeros by 136.2% during the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company's stock valued at $7,383,000 after buying an additional 430,932 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in Omeros in the fourth quarter worth $1,488,000. Wellington Management Group LLP purchased a new stake in Omeros in the first quarter worth $1,118,000. Nuveen LLC purchased a new stake in Omeros in the first quarter worth $938,000. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Omeros in the fourth quarter worth $1,033,000. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.